Clinical trials targeting these cytokines in asthma or COPD have failed to demonstrate efficacy and with anti‐TNFα have led to increased adverse events suggesting that targeting inflammation in this group is unlikely to be a successful strategy. This evidence concerns the gene TNF and chronic obstructive pulmonary disease.